Brief: Bergenbio Receives Regulatory Approval To Commence Phase II Trial Of Bemcentinib For COVID-19 In India

Oncoinvent ASA

30/09/2020 20:49

Sept 30 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO RECEIVES REGULATORY APPROVAL TO COMMENCE PHASE
II TRIAL OF BEMCENTINIB FOR COVID-19 IN INDIA
    * STUDY WILL ENROL 120 HOSPITALISED COVID-19 PATIENTS
    * PATIENT DOSING IN INDIA IS DUE TO COMMENCE IN NEXT FEW
WEEKS
    * 60 PATIENTS WILL RECEIVE BEMCENTINIB (AS MONOTHERAPY OR IN
COMBINATION WITH STANDARD OF CARE MEDICATION)
    * RECEIVED REGULATORY APPROVAL FROM INDIA REGULATORY
AUTHORITY FOR
PHASE II CLINICAL TRIAL OF BEMCENTINIB FOR TREATMENT OF COVID-19
    * 60 PATIENTS IN CONTROL GROUP (RECEIVING STANDARD OF CARE
TREATMENT ONLY), ACROSS FIVE SITES IN SOUTH AFRICA AND SEVEN
SITES IN INDIA

Source text for Eikon:  ID:nWkr5PkShX 
Further company coverage:  BGBIO.OL 

 ((Reuters.Briefs@thomsonreuters.com;))